Insight Molecular Diagnostics Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
IMDX$2.50+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
December 31, 2025
| PageNumber | |||
|---|---|---|---|
| Cautionary Note Regarding Forward-Looking Statements | 2 | ||
| Industry and Market Data | 3 | ||
| Part I | Item 1. | Business | 6 |
| Item 1A. | Risk Factors | 18 | |
| Item 1B. | Unresolved Staff Comments | 39 | |
| Item 1C. | Cybersecurity | 39 | |
| Item 2. | Properties | 39 | |
| Item 3. | Legal Proceedings | 40 | |
| Item 4. | Mine Safety Disclosures | 40 | |
| Part II | Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 41 |
| Item 6. | [Reserved] | 41 | |
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 42 | |
| Item 7A. | Quantitative and Qualitative Disclosures about Market Risk | 53 | |
| Item 8. | Financial Statements and Supplementary Data | 54 | |
| Item 9. | Changes in and Disagreements With Accountants on Accounting and Financial Disclosure | 54 | |
| Item 9A. | Controls and Procedures | 54 | |
| Item 9B. | Other Information | 55 | |
| Item 9C. | Disclosure Regarding Foreign Jurisdictions That Prevent Inspections | 55 | |
| Part III | Item 10. | Directors, Executive Officers and Corporate Governance | 56 |
| Item 11. | Executive Compensation | 56 | |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 56 | |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence | 56 | |
| Item 14. | Principal Accountant Fees and Services | 56 | |
| Part IV | Item 15. | Exhibits and Financial Statement Schedules | 57 |
| Signatures | 63 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.